What Does Tessera Therapeutics Do?

Total employees550
HeadquartersSomerville
Founded2018

Tessera Therapeutics is a life sciences company founded by Flagship Pioneering. They are developing a new category of genetic medicine known as Gene Writing™ technology. This technology aims to overcome the limitations of existing gene editing and gene therapy approaches by efficiently writing therapeutic messages into the genome to treat and cure diseases. Tessera's platform has the potential to make precisely targeted and highly efficient changes to the genome, including inserting or deleting, and rewriting, genes of any length.

Where Is Tessera Therapeutics's Headquarters?

Tessera Therapeutics officeTessera Therapeutics officeTessera Therapeutics officeTessera Therapeutics office
*Images sourced via web search. Rights belong to original owners

HQ Function

Primary hub for research and development, corporate operations, laboratory work, and strategic leadership in advancing Gene Writing technology.

Notable Features:

State-of-the-art laboratory facilities, modern collaborative workspaces, and located within a thriving biotechnology and life sciences cluster near Boston/Cambridge.

Work Culture:

An innovative, science-driven, and collaborative environment focused on pioneering genetic medicines. The culture emphasizes cutting-edge research, teamwork, and a strong mission to impact human health.

HQ Significance:

Serves as the central nervous system for Tessera's groundbreaking research, platform development, and efforts to bring Gene Writing therapies to patients.

Values Reflected in HQ: The headquarters' advanced infrastructure and strategic location reflect Tessera's commitment to scientific excellence, innovation, and attracting top talent to solve complex biological challenges.

Location:

Tessera Therapeutics is primarily focused on its research and development operations within the United States, with its main campus located in Somerville, Massachusetts. While their therapeutic ambitions and potential market reach are global, their physical office and laboratory presence is currently concentrated in the U.S. to foster close-knit collaboration for their pioneering Gene Writing platform.

Street Address:

100 South St

City:

Somerville

State/Province:

Massachusetts

Country:

USA

Where Else Does Tessera Therapeutics Operate Around the World?

Somerville, MA, USA

Address: 100 South St (Main Campus)

This site serves as the core innovation and operational hub, strategically positioned within the Boston-area biotechnology ecosystem to leverage talent and collaborations.

Buying Intent Signals for Tessera Therapeutics

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Who's Leading Tessera Therapeutics? Meet the Executive Team

As of April 2025, Tessera Therapeutics' leadership includes:

Michael Severino, M.D. - Chief Executive Officer & Director
Mary Rozenman, Ph.D. - Chief Financial Officer & Chief Business Officer
Howard Stern, M.D., Ph.D. - Chief Scientific Officer
David Chang, M.D., Ph.D. - Chief Medical Officer & Head of Portfolio Strategy
Lin Guey, Ph.D. - Chief Technology Officer
Hari Pujar, Ph.D. - Chief Operating Officer
Anne-Virginie Eggimann, J.D. - Chief Regulatory Officer
Rebecca Dabora, M.S. - Chief People Officer

Who's Investing in Tessera Therapeutics?

Tessera Therapeutics has been backed by several prominent investors over the years, including:

Flagship Pioneering
ARCH Venture Partners
Mubadala Investment Company
SoftBank Vision Fund 2
Qatar Investment Authority
Altitude Life Science Ventures
Alaska Permanent Fund Corporation

What Leadership Changes Has Tessera Therapeutics Seen Recently?

Hire4
Exits0

Tessera Therapeutics has made several key executive appointments in the past 12 months to strengthen its leadership team, particularly in scientific, technological, financial, and regulatory domains. No major C-suite departures have been publicly announced during this period.

New Appointments:

Mary Rozenman, Ph.D., Mary Rozenman appointed as CFO & CBO, bringing extensive experience in biotech finance and business development.
Lin Guey, Ph.D., Lin Guey joined Tessera as CTO to lead technology development for the Gene Writing platform.
Howard Stern, M.D., Ph.D., Howard Stern appointed as CSO to drive the scientific strategy and research efforts.
Anne-Virginie Eggimann, J.D., Anne-Virginie Eggimann joined as Chief Regulatory Officer to lead global regulatory strategy.

What Technology (Tech Stack) Is Used byTessera Therapeutics?

Discover the tools Tessera Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Tessera Therapeutics Email Formats and Examples

Tessera Therapeutics likely uses common professional email formats. The most probable format is [first_initial][last]@[domain] or [first].[last]@[domain].

[first_initial][last]@tessera.com

Format

jdoe@tessera.com

Example

90%

Success rate

What's the Latest News About Tessera Therapeutics?

Tessera Therapeutics Press ReleaseJanuary 18, 2024

Tessera Therapeutics Appoints Mary Rozenman, Ph.D., as Chief Financial Officer and Chief Business Officer

Tessera Therapeutics announced the appointment of Mary Rozenman, Ph.D., as Chief Financial Officer (CFO) and Chief Business Officer (CBO). Dr. Rozenman brings over 15 years of experience in biotech and pharma strategy, finance, and business development....more

Tessera Therapeutics Press ReleaseOctober 26, 2023

Tessera Therapeutics Appoints Lin Guey, Ph.D. as Chief Technology Officer

Tessera announced the appointment of Lin Guey, Ph.D., as Chief Technology Officer. Dr. Guey will be responsible for all aspects of technology development for Tessera's Gene Writing platform....more

Fierce BiotechApril 12, 2023

Flagship's gene writer Tessera nabs $300M+ to take RNA programs to clinic

Tessera Therapeutics secured over $300 million in a Series C financing round. The funds will be used to advance its Gene Writing platform and move multiple RNA-based therapeutic programs toward clinical development....more

Highperformr's free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Tessera Therapeutics, are just a search away.